METASTATIC COLORECTAL CANCER

This early-phase study tested the safety and best dose of combining two drugs, regorafenib and nivolumab, in 52 people with advanced colorectal cancer that had stopped responding to standard treatments. The goal was to see if this combination could help control the disease. Parti…

This study tested an experimental drug called CTX-009 in 49 adults with metastatic colorectal cancer that had worsened after two or three prior treatments. The goal was to see if the drug could shrink tumors or stop cancer growth. Participants received CTX-009 and were monitored …

This study tested a combination of two treatments (regorafenib and FOLFIRINOX) in 13 people with advanced colorectal cancer that has a specific gene change (RAS mutation). The main goal was to check safety and find the right dose. The study also looked at how long the cancer stay…

This study tested a new combination of drugs (encorafenib and cetuximab) against standard treatments in 107 Chinese patients with a specific genetic mutation (BRAF V600E) causing metastatic colorectal cancer. The goal was to see if the new combo could slow cancer growth better th…

This study tested whether adding the drug pembrolizumab to standard radiation or ablation could help the immune system attack tumors that were not directly treated. It involved 34 people with metastatic colorectal cancer who had already tried at least two standard treatments. The…

This study tested a new way of giving two cancer drugs—cetuximab and capecitabine—as a maintenance treatment for people with a specific type of metastatic colorectal cancer (KRAS/BRAF wild-type). The goal was to see if giving cetuximab every three weeks instead of weekly is safe …

This study tested whether adding the targeted drug panitumumab to a chemotherapy cocktail given directly into the liver could help keep colorectal cancer from returning after liver tumors were surgically removed. 75 patients with a specific gene type (wild-type RAS) and no cancer…

This study tested whether a new drug called A140 works as well as the standard drug Erbitux for people with a certain type of advanced colorectal cancer (RAS wild-type). Both drugs were given together with chemotherapy. The trial involved 688 adults who had not received chemother…

This study tested a combination of two drugs, sorafenib and irinotecan, in 64 adults with advanced colorectal cancer that had a specific gene change called K-RAS. The goal was to see if the combination could control the cancer after other treatments had stopped working. The study…

This study tested combinations of the drug etrumadenant (AB928) with other treatments in 227 adults whose colorectal cancer had spread. The goal was to see if these combos could shrink tumors or slow the disease. Participants had to be in fairly good health and have at least one …

This study allowed people with certain cancers (ovarian, basal cell, or colorectal) who had already shown benefit from the drug vismodegib in an earlier study to keep receiving it. The main goal was to track side effects and see how many people had to stop treatment due to them. …

This study tested a new immunotherapy called STIMVAX in 29 adults with metastatic colorectal cancer that had not responded to two prior treatments. The therapy uses immune cells from healthy donors to help the body fight cancer. Researchers measured how long patients lived and ch…

This study tested a new drug called ERAS-007 combined with other cancer treatments in 101 people with advanced colorectal or pancreatic cancer that had spread. The main goals were to find the safest dose and check for side effects. The approach targets a specific cell pathway (MA…

This study looked back at medical records of 274 people with a specific type of advanced colon cancer (BRAF V600E mutation) to see which treatments doctors used first and how well they worked. Since there is no standard targeted therapy for this cancer, the goal was to understand…

This study looked at past medical records of 121 people with metastatic colorectal cancer (advanced bowel cancer) in Europe. Researchers wanted to see how the order of taking two approved drug combinations—regorafenib and TAS (with or without bevacizumab)—affected treatment lengt…

This study looked at daily patterns of natural chemicals in urine from 32 people with advanced colorectal cancer and healthy volunteers. Researchers collected multiple urine samples over two days to measure these chemicals, along with a saliva sample to check clock genes. The goa…

This study tested whether early changes in blood markers (like CEA and tumor DNA) can predict if chemotherapy is working for people with metastatic colorectal cancer. 74 patients were followed for 3 months. The goal was to see if these blood tests could replace or supplement stan…

This study followed over 700 adults with metastatic colorectal cancer who took regorafenib as part of a French compassionate-use program. Researchers measured how long patients lived after starting the drug and looked at factors like tumor location and previous treatments. The go…

This study tested a new, non-invasive way to monitor chemotherapy in people with advanced colorectal cancer. Researchers used special sensors to measure chemicals called nucleosides in patients' urine before and after treatment. The goal was to see if these urine levels could sho…